search
Back to results

Study of Dosage Exploration and Pharmacokinetics for HA121-28 Tablets

Primary Purpose

Advanced Solid Tumor

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
HA121-28 tablets
HA121-28 tablets
HA121-28 tablets
HA121-28 tablets
HA121-28 tablets
HA121-28 tablets
HA121-28 tablets
HA121-28 tablets
Sponsored by
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Solid Tumor

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Be willing to participate in the clinical trial and sign the informed consent;
  2. Men and women aged 18 to 75 years;
  3. Histologically/cytologically confirmed advanced/metastatic solid tumor, and have failed prior standard therapy or for which no standard therapy is durable(patients with RET fusion/mutation can be included regardless of whether they have received standard therapy or not);
  4. At least one measurable lesion according to RECIST 1.1 ;
  5. Subject has not received any anti-cancer therapies including chemotherapy, radiotherapy, targeted treatment and surgery within 4 weeks prior to participation;
  6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0~1;
  7. Expected overall survival (Life expectancy)≥ 3 months;
  8. Laboratory test results must meet the following standards:

    Absolute neutrophil count (ANC) ≥1.5 x 10^9/L; Platelet count (PLT) ≥75×10^9/L; Hemoglobin (Hb) ≥90 g/L (no blood transfusion within 14 days); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x upper limit of normal (ULN) (in patients with liver metastasis ≤5.0 x ULN); Total bilirubin ≤ 1.5 x ULN; Serum creatinine≤ 1.5 x ULN;

  9. Male and female subjects of childbearing potential should agree to use suitable method of contraception during the treatment and 6 months after the last dose of study medication; female participants should have negative results of serum/urine pregnancy test within 7 days prior to enrollment and cannot be breastfeeding.

Exclusion Criteria:

  1. Has participated in other clinical trials and received the treatment within 4 weeks prior to enrollment;
  2. Patients who cannot swallow or have chronic diarrhea and intestinal obstruction, which may affect the administration and absorption of the drug;
  3. Subject who meets one of the following criteria:

    • Corrected QT (QTc) ≥470ms in women, ≥450ms in men; or congenital long QT syndrome (LQTS), taking QT prolonging medications, and has a family history of long QT syndrome;
    • Resting ECG result shows clinically significant abnormalities of rhythm, conduction or morphology, requiring therapeutic intervention;
  4. Urinalysis result shows protein in urine ≥ ++ and 24-hour urine protein > 1.0g;
  5. Based on the investigator's assessment, patients with known severe comorbidities which may influence the safety of the patients and the study completion [such as uncontrolled hypertension (systolic pressure ≥150 mmHg or diastolic pressure ≥100 mmHg, despite treated with the optimal medicine), diabetes, etc.];
  6. Patients who have symptoms of metastatic brain/meningeal tumors within 4 weeks of participation;
  7. Ongoing adverse events>grade 1 at the time of participation (except hair loss and pigmentation);
  8. Patients who have undergone major surgery or have not recovered from Invasive operation within 4 weeks prior to initiation of study treatment;
  9. Coagulation disorders (INR >1.5, prothrombin time (PT) > ULN+4s or APTT >1.5ULN): with bleeding diathesis (such as active peptic ulcer) or receiving thrombolytic or anti-coagulant treatment;
  10. Known pulmonary infection/ pneumonitis / interstitial pneumonia who are not suitable for the research;
  11. Known active Hepatitis B or Hepatitis C virus infection;

    • if HBsAg result is positive, additional HBV DNA testing is required (the result is higher than the ULN of the research center);
    • if HCV antibody result is positive, additional HCV RNA testing is required (the result is higher than the ULN of the research center);
  12. Known history of human immunodeficiency virus (HIV), or other acquired/congenital immune deficiency diseases or organ transplantation;
  13. Other anti-tumor therapies are required (including radiotherapy, chemotherapy, immunotherapy, targeted treatment, traditional Chinese medicine, etc.);
  14. Patients with known history of neurological or psychiatric disorders, including epilepsy or dementia;
  15. Not suitable for the treatment assessed by the researchers;
  16. Cardiac ejection fraction less than 50%;
  17. Patients who have suffered from or are complicated with any other malignant tumor within 5 years (except radically resected skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, local prostate cancer, in situ cervical cancer or other carcinoma in situ).

Sites / Locations

  • Sun Yat-sen University Cancer CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

HA121-28 tables

Arm Description

Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle

Outcomes

Primary Outcome Measures

Maximum Tolerated Dose (MTD) of HA121-28 tablets in Advanced and/or Metastatic Cancer Refractory to Standard Treatment
MTD defined by dose limiting toxicities (DLTs) that occur in the first cycle. DLT defined as any clinically grade 3 or 4 non-hematologic toxicity as defined in the NCI CTC v4.0

Secondary Outcome Measures

Antitumor Efficacy of HA121-28 tablets: RECIST criteria version 1.1.
Efficacy evaluation done using RECIST criteria version 1.1.

Full Information

First Posted
June 18, 2019
Last Updated
February 8, 2022
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03994484
Brief Title
Study of Dosage Exploration and Pharmacokinetics for HA121-28 Tablets
Official Title
Pharmacokinetics of Single and Multiple Doses of HA121-28 Tablets and Exploration of Maximum Tolerated Dose in Patients With Advanced Solid Tumor in PhaseⅠClinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 10, 2018 (Actual)
Primary Completion Date
December 30, 2022 (Anticipated)
Study Completion Date
December 30, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
There are 2 phases in this study: Phase 1 (dose escalation) and Phase 2 (dose expansion). The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of HA121-28 tablets that can be given to patients with advanced cancer. The goal of Phase 2 of this study is to learn if the dose of HA121-28 tablets found in Phase 1 can help to control advanced cancer. The safety of HA121-28 tablets will be studied in both phases of the study.
Detailed Description
If participants are found to be eligible to take part in this study, they will be assigned to a study group based on when they join this study. Up to 8 groups of up to 20 participants will be enrolled in Phase 1 of the study, and up to 3 groups of up to 24 participants will be enrolled in Phase 2. If participant is enrolled in Phase 1, the dose of HA121-28 tablets they receive will depend on when they join this study. The first group of participants will receive the lowest dose level of HA121-28 tablets. Each new group will receive a higher dose of HA121-28 tablets than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of HA121-28 tablets is found. If participant is enrolled in Phase 2, they will receive HA121-28 tablets at the low, medium and high doses to select the recommended dose for phase Ⅱ clinical trials.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Solid Tumor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
44 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
HA121-28 tables
Arm Type
Experimental
Arm Description
Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Intervention Type
Drug
Intervention Name(s)
HA121-28 tablets
Intervention Description
Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Intervention Type
Drug
Intervention Name(s)
HA121-28 tablets
Intervention Description
Participants will receive oral HA121-28 at a dose of 50 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Intervention Type
Drug
Intervention Name(s)
HA121-28 tablets
Intervention Description
Participants will receive oral HA121-28 at a dose of 100 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Intervention Type
Drug
Intervention Name(s)
HA121-28 tablets
Intervention Description
Participants will receive oral HA121-28 at a dose of 200 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Intervention Type
Drug
Intervention Name(s)
HA121-28 tablets
Intervention Description
Participants will receive oral HA121-28 at a dose of 300 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Intervention Type
Drug
Intervention Name(s)
HA121-28 tablets
Intervention Description
Participants will receive oral HA121-28 at a dose of 450 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Intervention Type
Drug
Intervention Name(s)
HA121-28 tablets
Intervention Description
Participants will receive oral HA121-28 at a dose of 600 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Intervention Type
Drug
Intervention Name(s)
HA121-28 tablets
Intervention Description
Participants will receive oral HA121-28 at a dose of 800 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
Primary Outcome Measure Information:
Title
Maximum Tolerated Dose (MTD) of HA121-28 tablets in Advanced and/or Metastatic Cancer Refractory to Standard Treatment
Description
MTD defined by dose limiting toxicities (DLTs) that occur in the first cycle. DLT defined as any clinically grade 3 or 4 non-hematologic toxicity as defined in the NCI CTC v4.0
Time Frame
At the end of Cycle 1 (each cycle is 28 days)
Secondary Outcome Measure Information:
Title
Antitumor Efficacy of HA121-28 tablets: RECIST criteria version 1.1.
Description
Efficacy evaluation done using RECIST criteria version 1.1.
Time Frame
up to 24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be willing to participate in the clinical trial and sign the informed consent; Men and women aged 18 to 75 years; Histologically/cytologically confirmed advanced/metastatic solid tumor, and have failed prior standard therapy or for which no standard therapy is durable(patients with RET fusion/mutation can be included regardless of whether they have received standard therapy or not); At least one measurable lesion according to RECIST 1.1 ; Subject has not received any anti-cancer therapies including chemotherapy, radiotherapy, targeted treatment and surgery within 4 weeks prior to participation; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0~1; Expected overall survival (Life expectancy)≥ 3 months; Laboratory test results must meet the following standards: Absolute neutrophil count (ANC) ≥1.5 x 10^9/L; Platelet count (PLT) ≥75×10^9/L; Hemoglobin (Hb) ≥90 g/L (no blood transfusion within 14 days); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x upper limit of normal (ULN) (in patients with liver metastasis ≤5.0 x ULN); Total bilirubin ≤ 1.5 x ULN; Serum creatinine≤ 1.5 x ULN; Male and female subjects of childbearing potential should agree to use suitable method of contraception during the treatment and 6 months after the last dose of study medication; female participants should have negative results of serum/urine pregnancy test within 7 days prior to enrollment and cannot be breastfeeding. Exclusion Criteria: Has participated in other clinical trials and received the treatment within 4 weeks prior to enrollment; Patients who cannot swallow or have chronic diarrhea and intestinal obstruction, which may affect the administration and absorption of the drug; Subject who meets one of the following criteria: Corrected QT (QTc) ≥470ms in women, ≥450ms in men; or congenital long QT syndrome (LQTS), taking QT prolonging medications, and has a family history of long QT syndrome; Resting ECG result shows clinically significant abnormalities of rhythm, conduction or morphology, requiring therapeutic intervention; Urinalysis result shows protein in urine ≥ ++ and 24-hour urine protein > 1.0g; Based on the investigator's assessment, patients with known severe comorbidities which may influence the safety of the patients and the study completion [such as uncontrolled hypertension (systolic pressure ≥150 mmHg or diastolic pressure ≥100 mmHg, despite treated with the optimal medicine), diabetes, etc.]; Patients who have symptoms of metastatic brain/meningeal tumors within 4 weeks of participation; Ongoing adverse events>grade 1 at the time of participation (except hair loss and pigmentation); Patients who have undergone major surgery or have not recovered from Invasive operation within 4 weeks prior to initiation of study treatment; Coagulation disorders (INR >1.5, prothrombin time (PT) > ULN+4s or APTT >1.5ULN): with bleeding diathesis (such as active peptic ulcer) or receiving thrombolytic or anti-coagulant treatment; Known pulmonary infection/ pneumonitis / interstitial pneumonia who are not suitable for the research; Known active Hepatitis B or Hepatitis C virus infection; if HBsAg result is positive, additional HBV DNA testing is required (the result is higher than the ULN of the research center); if HCV antibody result is positive, additional HCV RNA testing is required (the result is higher than the ULN of the research center); Known history of human immunodeficiency virus (HIV), or other acquired/congenital immune deficiency diseases or organ transplantation; Other anti-tumor therapies are required (including radiotherapy, chemotherapy, immunotherapy, targeted treatment, traditional Chinese medicine, etc.); Patients with known history of neurological or psychiatric disorders, including epilepsy or dementia; Not suitable for the treatment assessed by the researchers; Cardiac ejection fraction less than 50%; Patients who have suffered from or are complicated with any other malignant tumor within 5 years (except radically resected skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, local prostate cancer, in situ cervical cancer or other carcinoma in situ).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Wen Xu
Phone
1850063169
Email
xuwen@mail.ecspc.com
First Name & Middle Initial & Last Name or Official Title & Degree
Chuan Yang
Phone
18224456799
Email
yangchuan@mail.ecspc.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wen Xu
Organizational Affiliation
Clinical Medicine Department CSPC R&D Business Division
Official's Role
Study Director
Facility Information:
Facility Name
Sun Yat-sen University Cancer Center
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xu

12. IPD Sharing Statement

Learn more about this trial

Study of Dosage Exploration and Pharmacokinetics for HA121-28 Tablets

We'll reach out to this number within 24 hrs